The Ministry of Health from Junta de Andalucía (regional government) has granted our group, and specifically to Dr. Isabel González-Mariscal, another “Nicolás Monardes” tenure-track position. These contracts represent the highest step in the hospital research career. With this, the continuity of Dr. González in our group is guaranteed, allowing her to continue developing her research in type 1 diabetes. This is great news that rewards her enormous work in recent years, and also represents recognition to the collective effort of the research group.
The results of the PLATEDIAN study, in which three members of our group participated, have just been published in the prestigious journal Diabetes Care. Specifically, the study shows that the use of telemedicine in patients with type 1 diabetes and glycosylated haemoglobin less than 8% leads to similar therapeutic benefits in terms of efficacy and safety as face-to-face visits. This finding paves the way for using telemedicine in favour of greater comfort for these patients. You can consult this study at https://care.diabetesjournals.org/content/early/2019/12/11/dc19-0739
Yesterday we presented at the XXX Congress of the Spanish Diabetes Society, which is being held these days in Seville, interesting preliminary results on the beneficial effects of the synthetic cannabinoid Abn-
CBD in animal models of type 1 diabetes. Specifically, this compound seems to counteract the insulitis, (inflammation and infiltration of immune cells in the pancreatic islets that triggers the death of insulin-producing cells) as well as improve the inflammatory and oxidative profile at both the systemic and
pancreatic levels.
Yesterday our group participated with different activities in the European Researchers’ Night, in the Park of Malaga and the Rectorate of the University of Malaga, an annual event that aims to disseminate and sensitize citizens about the importance of research for today's society of well-being and, specifically, for searching new treatments for diseases such as diabetes and for improving citizen’s quality of life. Specifically, we have presented to the public the research we carry out in diabetes, as well as the importance of the use of animal models in current biomedical research. You can have more information at https://www.diariosur.es/malaga-capital/ciencia-sale-calle-20180929000930-
nt.html
Several members of our research group have been received in San Telmo palace by the president of the Junta de Andalucía, Ms. Susana Díaz. This invitation responds to our participation in a study recently published in the prestigious journal Nature Communications, directed by Dr. Benoit Gauthier from CABIMER (Seville), where it is shown that activation of LRH-1 receptor reduces the intensity of the autoimmune attack during type 1 diabetes onset while promotes the regeneration of insulin-producing beta cells. This study is available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902555/
Dr. Isabel González Mariscal joins our group with a MARIE SKLODOWSKA-CURIE INDIVIDUAL FELLOWSHIPS postdoctoral research contract. Dr. González-Mariscal comes from the National Institute of Aging of the NIH, Baltimore, USA, where she has been working for the last 7 years. She received a doctorate in Biotechnology from the Pablo de Olavide University in Seville in 2011, and then went to the US where she has been investigating until now. She is an expert in the study of new drugs against diabetes at the preclinical research level, and especially those related to the type 1 cannabinoid receptor (CB1). The contract that is now starting has a duration of 2 years and is funded by the European Union.
